question,rag_answer,expected_answer,manual_accuracy_score,manual_citation_score,timestamp,assessment_type
is preoperative echocardiography recommended for patients with suspected moderate or severe valvular disease?,"**Preoperative Echocardiography in Patients with Suspected Moderate or Severe Valvular Disease** According to the 2017 CCS Guidelines on Cardiac Risk for Non-Cardiac Surgery, preoperative resting echocardiography is not recommended for patients undergoing non-cardiac surgery to enhance perioperative cardiac risk estimation (Strong Recommendation; Low Quality Evidence) [Source: 2017 CCS Guidelines on Cardiac Risk for Non-Cardiac Surgery.md]. However, the same guidelines suggest that urgent echocardiography should be obtained before surgery in patients with clinical examination suggesting undiagnosed severe obstructive intracardiac abnormality (e.g., aortic stenosis, mitral stenosis, hypertrophic obstructive cardiomyopathy) or severe pulmonary hypertension [Source: 2017 CCS Guidelines on Cardiac Risk for Non-Cardiac Surgery.md]. In contrast, the 2014 ACC/AHA Guideline on Cardiac Risk for Non-Cardiac Surgery recommends that patients with suspected valvular heart disease should undergo echocardiography to quantify the severity of stenosis or regurgitation, calculate systolic function, and estimate right heart pressures [Source: 2014 ACC_AHA Guideline on Cardiac Risk for Non-Cardiac Surgery.md]. Moreover, the 2014 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease suggests that patients with significant valvular heart disease should have an accurate diagnosis of the type and severity of valvular heart disease before non-cardiac surgery, and that echocardiography is an essential tool for this purpose [Source: 2014 ACC_AHA Guideline for the Management of Patients With Valvular Heart Disease.md]. **Recommendations:** * For patients with suspected moderate or severe valvular disease, routine preoperative resting echocardiography is not recommended.
* However, urgent echocardiography should be obtained before surgery in patients with clinical examination suggesting undiagnosed severe obstructive intracardiac abnormality or severe pulmonary hypertension.
* Patients with significant valvular heart disease should have an accurate diagnosis of the type and severity of valvular heart disease before non-cardiac surgery, and echocardiography is an essential tool for this purpose. **Critical Clinical Recommendations:** * Patients with suspected valvular heart disease should undergo echocardiography to quantify the severity of stenosis or regurgitation, calculate systolic function, and estimate right heart pressures.
* Echocardiography should be performed in patients with clinical examination suggesting undiagnosed severe obstructive intracardiac abnormality or severe pulmonary hypertension before non-cardiac surgery.
* Patients with significant valvular heart disease should have an accurate diagnosis of the type and severity of valvular heart disease before non-cardiac surgery, and echocardiography is an essential tool for this purpose.","Yes, echocardiography is recommended for patients with suspected moderate or greater valvular stenosis or regurgitation.",3,3,20251112_083905,manual
should perioperative pain management strategies be individualized to minimize hemodynamic stress?,"**Individualized Perioperative Pain Management Strategies to Minimize Hemodynamic Stress** Perioperative pain management strategies should be individualized to minimize hemodynamic stress, as it can have significant implications for patient outcomes. The American Society of Regional Anesthesia and Pain Medicine (ASRA) guidelines (2025) [Source: ASRA Guidelines 2025.md] emphasize the importance of tailoring pain management plans to each patient's unique needs and medical history. **Evidence-Based Recommendations** * Multimodal analgesia is a key component of perioperative pain management. This approach involves combining different types of analgesics, such as acetaminophen, NSAIDs, and opioids, to achieve optimal pain relief while minimizing side effects [Source: Anesthesia Notes.md].
* Regional anesthesia techniques, such as peripheral nerve blocks and neuraxial anesthesia, can be effective in reducing hemodynamic stress and providing postoperative pain relief [Source: ASRA Guidelines 2025.md].
* Continuous infusion of opioids or local anesthetics can provide sustained pain relief and reduce the need for systemic opioids, which can contribute to hemodynamic instability [Source: 2019 PAIN Suboxone Guidelines.md].
* Patient-controlled analgesia (PCA) can allow patients to self-administer pain medication, which can help reduce hemodynamic stress and improve patient satisfaction [Source: 2019 PAIN Suboxone Guidelines.md]. **Special Considerations** * Patients undergoing high-risk surgery, such as aortic aneurysm repair, may require specialized anesthesia care to minimize hemodynamic stress and optimize postoperative outcomes [Source: Anesthetic Considerations - tlb.md].
* Patients with comorbidities, such as cardiovascular disease or chronic kidney disease, may require careful consideration of pain management strategies to minimize hemodynamic stress and prevent complications [Source: Anesthetic Considerations - tlb.md]. **Conclusion** Perioperative pain management strategies should be individualized to minimize hemodynamic stress and optimize patient outcomes. By considering the patient's unique needs and medical history, anesthesiologists can develop effective pain management plans that balance pain relief with the need to minimize hemodynamic stress.","Yes, pain management should be tailored to minimize hemodynamic fluctuations.",3,3,20251112_083905,manual
Is routine iron or erythropoietin therapy recommended in ICU anaemia?,"**Routine Iron or Erythropoietin Therapy in ICU Anemia** Based on the provided clinical guidelines and medical literature, routine iron or erythropoietin therapy is not recommended for treating anemia in critically ill patients in the ICU. [Source: Blood components updated V2 final.md]
Available evidence does not support the routine use of iron therapy and/or erythropoietin to treat anaemia in patients who are critically ill. [Source: Blood components updated V2 final.md]
In critically ill patients, anemia is common and associated with poor short and long-term clinical outcomes. Haemoglobin drops by a mean (SD) of 0.52 (0.69) g.l-1 per day whilst on ICU [70]. However, a restrictive transfusion threshold of Hb < 70 g.l-1 is recommended in most patients, including those with ARDS and septic shock [73, 74]. **Strategies to Minimize Iatrogenic Anemia** Instead of routine iron or erythropoietin therapy, the following strategies are recommended to minimize iatrogenic anemia in critically ill patients: * Limit blood sampling by using small-volume tubes [78].
* Avoid standing orders for blood draws.
* Use blood conservation devices.
* Manage medications likely to cause anemia and/or bleeding. [Source: Blood components updated V2 final.md]
A large cluster, multicentre RCT found that the use of small-volume tubes in the ICU may decrease RBC transfusions without affecting laboratory analysis [78], and their use is now recommended by international guidelines [79]. **Treatment of Iron Deficiency Anemia** If iron deficiency anemia is diagnosed, treatment with ferrous iron salts administered orally is recommended. Iron stores are replenished slowly, and therapy should be continued for at least 1 year after the source of blood loss that caused the iron deficiency is corrected [20_Stoelting.md]. **Blood Product Administration** Once hemorrhage control is achieved, blood product administration should be guided by regular laboratory and/or VHA testing. Target endpoints for resuscitation include a pH > 7.2, and normalizing base deficit and lactate [Blood components updated V2 final.md]. **Restrictive Transfusion Threshold** A restrictive transfusion threshold of Hb < 70 g.l-1 is recommended in most patients, including those with ARDS and septic shock [73, 74]. However, the optimal transfusion threshold remains uncertain in patients with acute coronary syndromes or ischemic heart disease. **Conclusion** In conclusion, routine iron or erythropoietin therapy is not recommended for treating anemia in critically ill patients in the ICU. Instead, strategies to minimize iatrogenic anemia, such as using small-volume tubes and managing medications likely to cause anemia and/or bleeding, should be implemented. Treatment of iron deficiency anemia with ferrous iron salts administered orally and a restrictive transfusion threshold of Hb < 70 g.l-1 are recommended.","No, routine use of iron or erythropoietin is not recommended for ICU patients.",3,3,20251112_083905,manual
What platelet threshold is recommended in obstetric haemorrhage?,"To determine the recommended platelet threshold in obstetric hemorrhage, we must consider the provided clinical guidelines and medical literature. According to the guidelines: * For patients with postpartum hemorrhage (PPH) or other obstetric hemorrhage, platelet transfusions are prescribed more commonly to treat thrombocytopaenia and prevent bleeding (prophylaxis) [Source: Blood components updated V2 final.md].
* However, recent trials have questioned the roles of platelet transfusions for either of these purposes, and the use of platelet transfusions remains controversial [44, 45].
* In the absence of active bleeding, the following platelet count thresholds should be applied: + Insertion or removal of epidural catheter: 80 × 10^9/L + Major surgery: 50 × 10^9/L + Neurosurgery or posterior segment ophthalmic surgery: 100 × 10^9/L + PPH: < 100 × 10^9/L or > 5000 mL [91]
* Platelet transfusion is required rarely unless PPH is > 5000 mL or platelet count is < 100 × 10^9/L from another cause prior to the PPH [91]. Based on the provided information, the recommended platelet threshold in obstetric hemorrhage is: * Platelet count < 100 × 10^9/L or > 5000 mL: Platelet transfusion is recommended.
* Platelet count between 50 and 100 × 10^9/L: Platelet transfusion may be considered, depending on the individual patient's risk factors and clinical situation. Please note that these recommendations are based on the provided context and may not reflect the most up-to-date or comprehensive clinical guidelines. It is essential to consult current clinical guidelines and protocols for the most accurate and evidence-based recommendations. Citations: [Source: Blood components updated V2 final.md]
[44-45] Recent trials questioning the roles of platelet transfusions
[91] Platelet transfusion is required rarely unless PPH is > 5000 mL or platelet count is < 100 × 10^9/L
[Source: 2025_CAS_Revised_Guidelines.md]
Platelet count thresholds for neuraxial techniques: C > 70 × 10^9/L, C 50-70 × 10^9/L, and C 50 × 10^9/L",Platelet transfusion should be given if platelet count is < 75 × 10⁹/L in obstetrics.,3,3,20251112_083905,manual
"following an accidental dural puncture with an epidural needle, what is the incidence of post dural puncture headache (PDPH)?","**Incidence of Postdural Puncture Headache (PDPH) following Accidental Dural Puncture with an Epidural Needle** According to the clinical guidelines and medical literature, the incidence of PDPH is approximately 1% following any neuraxial procedure [Source: 2025_CAS_Revised_Guidelines.md]. However, it is greater than 50% following accidental dural puncture with a 16-18G epidural needle [Source: 2025_CAS_Revised_Guidelines.md]. **Risk Factors and Clinical Features** The size of the dural puncture is an important risk factor, with larger needles increasing the risk of PDPH [Source: 2025_CAS_Revised_Guidelines.md]. Additionally, features of PDPH include: * Typically frontal/occipital, often radiation to the neck, mild to incapacitating
* Postural component is a key feature, with symptoms worse upright and some relief horizontal [Source: Anesthesia Notes.md]
* Onset is usually 1-2 days after the dural puncture, with symptoms lasting less than 1 week in 93% of cases [Source: Anesthesia Notes.md]
* Associated symptoms include nausea (60%), vomiting (24%), neck stiffness (43%), ocular symptoms (13%), and auditory symptoms (12%) [Source: Anesthesia Notes.md] **Diagnosis and Management** The diagnosis of PDPH is clinical, with imaging not recommended unless symptoms suggest another diagnosis [Source: Anesthesia Notes.md]. Conservative treatments include: * Combination of bed rest and hydration (oral or intravenous)
* Oral analgesics, including acetaminophen, nonsteroidal anti-inflammatories, and opioids as needed
* A single 300-mg dose of oral caffeine
* Sphenopalatine ganglion blocks performed by a skilled operator [Source: 2025_CAS_Revised_Guidelines.md] **Epidural Blood Patch** Epidural blood patch is a treatment for PDPH, with symptoms relieved within 1-24 hours in 85-95% of patients [Source: Anesthesia Notes.md]. The most common side effects are backache and radicular pain [Source: Anesthesia Notes.md]. The timing of epidural blood patch is controversial, with prophylactic blood patch may or may not be effective [Source: Anesthesia Notes.md]. **Other Treatment Options** Other treatment options for PDPH include: * Epidurally administered fibrin glue, which has been shown to be an effective alternative to blood administration [Source: Anesthesia Notes.md]
* Prophylactic measures, including abdominal binder and prophylactic epidural dextran, which have been shown to be ineffective [Source: Anesthesia Notes.md]",greater than 50%,3,3,20251112_083905,manual
what is a hypertensive emergency?,"A hypertensive emergency is a medical condition characterized by a sudden, severe increase in blood pressure that is accompanied by evidence of acute or ongoing target organ damage. According to the provided clinical guidelines and medical literature, a hypertensive emergency is typically defined as a blood pressure of more than 180/120 mm Hg, with or without evidence of target organ damage (Stoelting, 05_Stoelting.md). The target organs that are most commonly affected in hypertensive emergencies include the brain (encephalopathy, intracerebral hemorrhage), the heart (acute left ventricular failure with pulmonary edema, unstable angina), and the kidneys (renal injury or failure). The objectives of treating severe hypertension in patients with hypertensive emergencies are to prevent congestive heart failure, myocardial ischemia, renal injury or failure, and ischemic or hemorrhagic stroke (ACOG, 2018 ACOG Pre-Eclampsia Guidelines.md). Antihypertensive treatment should be initiated expeditiously for acute-onset severe hypertension (systolic blood pressure of 160 mm Hg or more or diastolic blood pressure of 110 mm Hg or more, or both) that is confirmed as persistent (15 minutes or more) (ACOG, 2018 ACOG Pre-Eclampsia Guidelines.md). The most commonly used antihypertensive agents for treating hypertensive emergencies include intravenous hydralazine, labetalol, and oral nifedipine (ACOG, 2018 ACOG Pre-Eclampsia Guidelines.md). In patients with hypertensive emergencies, the mode of delivery in women with gestational hypertension or preeclampsia (with or without severe features) should be determined by routine obstetric considerations. Vaginal delivery often can be accomplished, but with labor induction in preeclampsia with severe features this is less likely with decreasing gestational age at diagnosis (ACOG, 2018 ACOG Pre-Eclampsia Guidelines.md). In summary, a hypertensive emergency is a medical condition characterized by a sudden, severe increase in blood pressure that is accompanied by evidence of acute or ongoing target organ damage. The objectives of treating severe hypertension in patients with hypertensive emergencies are to prevent congestive heart failure, myocardial ischemia, renal injury or failure, and ischemic or hemorrhagic stroke. Antihypertensive treatment should be initiated expeditiously, and the most commonly used antihypertensive agents include intravenous hydralazine, labetalol, and oral nifedipine. References: * ACOG (2018 ACOG Pre-Eclampsia Guidelines.md). Guidelines for the Management of Hypertension in Pregnancy.
* ACOG (2020 ACOG Pre-Eclampsia.md). Practice Bulletin Gestational Hypertension and Preeclampsia.
* Stoelting (05_Stoelting.md). Pharmacology and Physiology in Anesthetic Practice (6th ed.).","hypertensive emergency is when hypertensive patients have acute or ongoing end organ damage from hypertension, typically with a blood pressure more than 180/120",3,3,20251112_083905,manual
is it recommended to measure preoperative natriuretic peptides in high-risk patients undergoing vascular surgery?,"**Recommendation for Measuring Preoperative Natriuretic Peptides in High-Risk Patients Undergoing Vascular Surgery** According to the 2014 ACC/AHA Guideline on Cardiac Risk for Non-Cardiac Surgery, preoperative natriuretic peptide levels independently predict cardiovascular events in the first 30 days after vascular surgery [1]. Specifically, measurement of biomarkers, especially natriuretic peptides, may be helpful in assessing patients with heart failure (HF) and with diagnosing HF as a postoperative complication in patients at high risk for HF [2]. A systematic review and individual patient data meta-analysis found that preoperative and postoperative B-type natriuretic peptides (BNP) significantly improved the predictive performance of the Revised Cardiac Risk Index (RCRI) for perioperative cardiac events [3]. Another study found that plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) was an independent predictor of postoperative cardiac events in patients undergoing surgery for abdominal aortic aneurysm or leg bypass [4]. However, the guideline also notes that further prospective randomized studies are needed to assess the utility of measuring preoperative natriuretic peptides as a strategy to reduce postoperative cardiac risk [2]. Additionally, the guideline highlights that biomarkers may provide incremental predictive value, but there are no data to suggest that targeting these biomarkers for treatment and intervention will reduce the postoperative risk [5]. **Key Recommendations:** * Measure preoperative natriuretic peptide levels in high-risk patients undergoing vascular surgery to independently predict cardiovascular events in the first 30 days after surgery.
* Consider using preoperative natriuretic peptide levels as part of a comprehensive risk assessment strategy to identify patients at highest risk for perioperative cardiac events.
* However, do not rely solely on biomarkers to guide treatment and intervention, and instead, use them as part of a multidisciplinary approach to perioperative care. **References:** [1] Rodseth RN, Lurati Buse GA, Bolliger D, et al. The predictive ability of pre-operative B-type natriuretic peptide in vascular patients for major adverse cardiac events: an individual patient data meta-analysis. J Am Coll Cardiol. 2011;58:522-9. [2] 2014 ACC/AHA Guideline on Cardiac Risk for Non-Cardiac Surgery.md [3] Rodseth RN, Biccard BM, Le MY, et al. The prognostic value of preoperative and post-operative B-type natriuretic peptides in patients undergoing noncardiac surgery: B-type natriuretic peptide and N-terminal fragment of pro-B-type natriuretic peptide: a systematic review and individual patient data meta-analysis. J Am Coll Cardiol. 2014;63:170-80. [4] Feringa HHH, Schouten O, Dunkelgrun M, et al. Plasma N-terminal proB-type natriuretic peptide as long-term prognostic marker after major vascular surgery. Heart. 2007;93:226-31. [5] 2014 ACC/AHA Guideline on Cardiac Risk for Non-Cardiac Surgery.md","Yes, measurement of natriuretic peptides may be useful in high-risk vascular surgery patients.",3,3,20251112_083905,manual
how long should a patient be monitored after an epidural blood patch?,"**Monitoring After an Epidural Blood Patch** Patients who undergo an epidural blood patch should be monitored for a period of time to ensure the procedure is effective and safe. According to the 2025_CAS_Revised_Guidelines.md, for patients with mild PDPH without associated cranial symptoms, conservative treatments are recommended. However, for patients with moderate and severe PDPH with associated cranial symptoms who are unresponsive to conservative management or with symptoms that are interfering with activities of daily living, an epidural blood patch should be offered. The guidelines state that there is insufficient evidence to recommend a specific pathway of care after an epidural blood patch, but the convention is to keep the patient supine, monitor them with CAS monitors for one to two hours, and to instruct them to avoid straining activities involving Valsalva maneuvers. In the Anesthesia Notes.md, it is stated that symptoms are relieved within 1 to 24 hours in 85 to 95% of patients who undergo an epidural blood patch. The most common side effects of blood patch are backache and radicular pain, and transient bradycardia and cranial nerve palsies have also been reported. Based on the available information, it appears that patients should be monitored for at least one to two hours after an epidural blood patch, as recommended by the convention. However, the exact duration of monitoring may vary depending on individual patient factors and the severity of symptoms. **Key Points** * Patients with moderate and severe PDPH with associated cranial symptoms who are unresponsive to conservative management or with symptoms that are interfering with activities of daily living should be offered an epidural blood patch.
* The convention is to keep the patient supine, monitor them with CAS monitors for one to two hours, and to instruct them to avoid straining activities involving Valsalva maneuvers.
* Symptoms are relieved within 1 to 24 hours in 85 to 95% of patients who undergo an epidural blood patch.
* The most common side effects of blood patch are backache and radicular pain, and transient bradycardia and cranial nerve palsies have also been reported. **References** [Source: 2025_CAS_Revised_Guidelines.md]
* For patients with mild PDPH without associated cranial symptoms, conservative treatments are recommended.
* For patients with moderate and severe PDPH with associated cranial symptoms who are unresponsive to conservative management or with symptoms that are interfering with activities of daily living, an epidural blood patch should be offered.
* The convention is to keep the patient supine, monitor them with CAS monitors for one to two hours, and to instruct them to avoid straining activities involving Valsalva maneuvers. [Source: Anesthesia Notes.md]
* Symptoms are relieved within 1 to 24 hours in 85 to 95% of patients who undergo an epidural blood patch.
* The most common side effects of blood patch are backache and radicular pain, and transient bradycardia and cranial nerve palsies have also been reported.",usually one to two hours in the supine position,3,3,20251112_083905,manual
What is the recommended transfusion threshold for FFP in major haemorrhage?,"**Recommended Transfusion Threshold for FFP in Major Haemorrhage** The recommended transfusion threshold for Fresh Frozen Plasma (FFP) in major haemorrhage is not explicitly stated in the provided context. However, based on the information provided, it is recommended to transfuse FFP in a more balanced ratio with Red Blood Cells (RBCs), usually 1:1 or 1:1.5, until results of coagulation tests are available. **Guidelines for Transfusion in Major Haemorrhage** The guidelines for transfusion in major haemorrhage are as follows: * Transfuse RBCs and FFP in preference to clear fluids (crystalloids) unless there is profound hypotension and no imminent availability of blood components .
* Monitor patients who continue to bleed actively by point-of-care and/or regular laboratory tests for coagulation, fibrinogen, and platelet counts and/or function .
* A guide for transfusion is: + FFP if INR > 1.5 + Cryoprecipitate if fibrinogen < 1.5 g/l (- 2.0 g/l in obstetrics) + Platelets if platelet count < 50 × 10^9/l (- 75 × 10^9/l in obstetrics) . **Ratio of FFP to RBCs** A higher ratio of FFP and platelets to RBCs is believed to significantly decrease the risk of coagulation abnormalities during massive peripartum resuscitation . This opinion is based on the literature discussed earlier on damage control resuscitation and the fact that a mixture of 1 unit of PRBCs, 1 unit of FFP, and 1 unit of platelets has a hematocrit of 29%, a platelet count of 85,000/mm^3, and coagulation factor activity of 62%. **Monitoring** Monitoring should include: * PTT, PT, platelet count, and fibrinogen level measured at baseline and every hour after the initiation of massive transfusion to guide therapy .
* Use of point-of-care devices such as a thromboelastograph or thromboelastometer may improve assessment of hemostasis and provide goal-directed hemostatic therapy .
* Plasma electrolyte levels should also be measured at baseline and every hour after the initiation of massive transfusion, with specific assessment for hyperkalemia, hypomagnesemia, hypocalcemia, and hyperchloremia . **Factor VII** A dose of 80 to 95 mcg/kg of factor VII may stop or reduce hemorrhage without an increase in the incidence of thromboembolic events . Failure of this therapy to correct coagulopathy may be due to hypothermia, acidosis, or low fibrinogen level.",FFP is recommended if INR > 1.5.,3,3,20251112_083905,manual
Should all patients have their haemoglobin concentration measured before major elective surgery?,"**Recommendation:** Based on the provided context and clinical guidelines, it is not strictly necessary to measure the haemoglobin concentration in all patients before major elective surgery. However, certain patient groups may benefit from preoperative haemoglobin measurement. **Clinical Considerations:** * Patients who are haemodynamically stable and without evidence of active bleeding may not require preoperative haemoglobin measurement [Source: Blood components updated V2 final.md]
* Patients who are actively bleeding or at risk of bleeding, such as those undergoing orthopaedic surgery, critical care, vascular surgery, or cardiac surgery, may benefit from preoperative haemoglobin measurement and a restrictive transfusion strategy (maintaining Hb between 70 and 80g/l) [Source: Blood components updated V2 final.md]
* Certain clinical subgroups, such as those with acute coronary syndromes, acute brain injury, active cancer, and older patients, may require higher haemoglobin thresholds (80-100 g/l) until the results of ongoing trials are available [Source: Blood components updated V2 final.md]
* In patients who are haemodynamically stable and not bleeding, haemoglobin concentration is the most common clinical measurement used to guide RBC transfusion [Source: Blood components updated V2 final.md] **Clinical Judgment:** Preoperative haemoglobin measurement should be used judiciously and based on individual patient factors. Clinicians should consider the patient's overall health status, functional capacity, and the type of surgical procedure when deciding whether to measure haemoglobin concentration before surgery. **Key Takeaways:** * Preoperative haemoglobin measurement is not strictly necessary for all patients before major elective surgery.
* Certain patient groups, such as those at risk of bleeding or with specific clinical conditions, may benefit from preoperative haemoglobin measurement.
* Clinical judgment and individual patient factors should guide the decision to measure haemoglobin concentration before surgery. **References:** [Source: Blood components updated V2 final.md]
[Source: 27_Stoelting.md]
[Source: 28_Stoelting.md] This response is based on the provided context and clinical guidelines. Clinical decision-making should always be guided by individual patient factors and clinical judgment.","Yes, all patients should have haemoglobin checked prior to major elective surgery.",3,3,20251112_083905,manual
what are classic physical exam findings of LV failure?,"**Classic Physical Exam Findings of LV Failure** Based on the provided clinical guidelines and medical literature, the following are the classic physical exam findings of left ventricular (LV) failure: * **Pulmonary Edema**: - Distention of the pulmonary veins in the upper lobes of the lungs - Perivascular edema appears as hilar or perihilar haze - Kerley's lines (edematous interlobular septae) may be present, producing a honeycomb pattern - Alveolar edema produces homogeneous densities in the lung fields, typically in a butterfly pattern [Source: 06_Stoelting.md] * **Cardiomegaly**: Enlarged cardiac silhouette on chest radiography [Source: 06_Stoelting.md] * **Pulmonary Venous Hypertension**: Distention of the pulmonary veins in the upper lobes of the lungs [Source: 06_Stoelting.md] * **Orthopnea**: Shortness of breath when lying flat and relieved by sitting up [Source: 2014 ACC_AHA Guideline on Cardiac Risk for Non-Cardiac Surgery.md] * **Paroxysmal Nocturnal Dyspnea (PND)**: Waking up at night with shortness of breath [Source: 2014 ACC_AHA Guideline on Cardiac Risk for Non-Cardiac Surgery.md] * **Bilateral Lung Crackles**: Sounds heard upon auscultation of the lungs, characteristic of pulmonary congestion [Source: 06_Stoelting.md] * **S3 Heart Sound**: Third heart sound, indicating LV failure [Source: 06_Stoelting.md] These physical exam findings are indicative of LV failure and should be used in conjunction with other diagnostic tools, such as echocardiography and chest radiography, to assess the patient's condition. **References** 1. [Source: 06_Stoelting.md]
2. [Source: 2014 ACC_AHA Guideline on Cardiac Risk for Non-Cardiac Surgery.md]","tachypnea and moist rales, resting tachycardia, s3 gallop.",3,3,20251112_083905,manual
what are anesthetic considerations for patients with aortic regurgitation,"**Anesthetic Considerations for Patients with Aortic Regurgitation** Aortic regurgitation (AR) is a valvular heart disease characterized by the leakage of the aortic valve, allowing blood to flow back into the left ventricle during diastole. Anesthetic management for patients with AR requires careful consideration of the pathophysiology and compensatory mechanisms to maintain forward left ventricular stroke volume. **Preoperative Evaluation** Preoperative evaluation of patients with AR involves assessing the severity of the valve disease, left ventricular function, and presence of symptoms (Source: 2014 ACC_AHA Guideline for the Management of Patients With Valvular Heart Disease.md). **Hemodynamic Goals** During anesthesia, the following hemodynamic goals are recommended: * Maintain a heart rate above 80 beats per minute to prevent bradycardia-induced left ventricular volume overload
* Avoid abrupt increases in systemic vascular resistance, which can precipitate left ventricular failure
* Maintain modest decreases in systemic vascular resistance to reduce afterload
* Use inotropes to increase contractility if left ventricular failure occurs **Induction of Anesthesia** Induction of anesthesia can be achieved with an inhaled anesthetic or an intravenous induction drug. Ideally, the induction drug should not decrease the heart rate or increase systemic vascular resistance (Source: 02_Stoelting.md). **Maintenance of Anesthesia** General anesthesia is the usual choice for patients with AR. Maintenance of anesthesia involves close monitoring of hemodynamic parameters to ensure the above-mentioned goals are met. **Clinical Considerations** * Bradycardia can occur during anesthesia, leading to left ventricular volume overload. Maintain a heart rate above 80 beats per minute.
* Abrupt increases in systemic vascular resistance can precipitate left ventricular failure. Avoid these increases.
* Use inotropes to increase contractility if left ventricular failure occurs.
* Close monitoring of hemodynamic parameters is crucial to ensure the above-mentioned goals are met. **References** [Source: 2014 ACC_AHA Guideline for the Management of Patients With Valvular Heart Disease.md]
[Source: 02_Stoelting.md] **Important Notes** * Anesthetic management for patients with AR requires careful consideration of the pathophysiology and compensatory mechanisms.
* Close monitoring of hemodynamic parameters is crucial to ensure the above-mentioned goals are met.
* Bradycardia, abrupt increases in systemic vascular resistance, and left ventricular failure are potential complications that require prompt recognition and management.","avoid bradycardia, avoid increases in systemic vascular resistance, minimize myocardial depression",3,3,20251112_083905,manual
What is the recommended oxygen saturation (SaO2) during one lung ventilation (OLV)?,"Based on the provided context, the recommended oxygen saturation (SaO2) during one lung ventilation (OLV) is between 92-96%. [Source: step by step management of onelung ventilation CJA 2014.md]
A FIO2 of 0.5-0.8 should be adequate at the beginning of OLV, and titrate F I O2 to a target SpO2 of 92-96%. **Important Patient Safety Consideration:**
High F I O2 may result in the production of reactive oxygen species (ROS) and pro-inflammatory cytokines, leading to lung damage. Therefore, titrating F I O2 to achieve the desired oxygen saturation is crucial. **Clinical Recommendation:**
During OLV, titrate F I O2 to a target SpO2 of 92-96% to minimize the risk of oxidative stress and lung damage.",92-96%,3,3,20251112_083905,manual
should perioperative statin therapy be initiated in vascular surgery patients not already on treatment?,"**Should perioperative statin therapy be initiated in vascular surgery patients not already on treatment?** Based on the provided clinical guidelines and medical literature, the answer is **yes**, perioperative statin therapy should be initiated in vascular surgery patients not already on treatment. **Class IIa Recommendation:** [Source: 2014 ACC_AHA Guideline on Cardiac Risk for Non-Cardiac Surgery.md]
Perioperative initiation of statin use is reasonable in patients undergoing vascular surgery. 287 (Level of Evidence: B) **Evidence from Studies:** * A randomized trial found a significant decrease in Major Adverse Cardiac Events (MACE) in patients on atorvastatin who were undergoing vascular surgery. * A Cochrane analysis of 3 studies found a trend toward reduced mortality in the statin group, although the estimates were derived from a single study population. **Benefits of Perioperative Statin Therapy:** * Reduced risk of perioperative MI or death at 2-year follow-up * Reduced risk of all-cause mortality rate **Mechanism of Benefit:** * The mechanism of benefit of statin therapy prescribed perioperatively to lower cardiac events is unclear and may be related to pleiotropic as well as cholesterol-lowering effects. **Conclusion:** Based on the Class IIa recommendation and the evidence from studies, it is reasonable to initiate perioperative statin therapy in vascular surgery patients not already on treatment. This may also provide an opportunity to impact long-term health in patients meeting indications for statin therapy.","Yes, initiating statin therapy is reasonable in vascular surgery patients not already receiving it.",3,3,20251112_083905,manual
what is the definition of pulmonary artery hypertension?,"**Definition of Pulmonary Artery Hypertension (PAH)** Pulmonary artery hypertension (PAH) is defined as an elevation of mean pulmonary arterial pressure to ≥ 25 mm Hg at rest. [Source: 2018 AHA_ACC Guidelines on Adult Congenital Heart Disease.md] **Classification of PAH** PAH is further classified on the basis of the presumed mechanism, including: * Elevation of pulmonary venous pressure (denoted as 'postcapillary pulmonary hypertension')
* Parenchymal or restrictive lung disease
* Rheumatologic disease
* Portal hypertension
* Toxin exposure
* Thromboembolism PAH is also classified by developmental or acquired anatomic abnormalities of decreased pulmonary arterial capacitance, impedance, or stenosis throughout the pulmonary arterial vascular bed. [Source: 2018 AHA_ACC Guidelines on Adult Congenital Heart Disease.md] **Pathophysiology of PAH** PAH develops as a result of pulmonary vascular remodeling and endothelial dysfunction, leading to increased pulmonary vascular resistance (PVR) and elevated pulmonary artery pressure. [Source: 05_Stoelting.md] **Diagnostic Studies for PAH** The laboratory evaluation and diagnostic studies used in the workup of pulmonary hypertension of any cause include: * Right-sided heart catheterization to determine disease severity and response to vasodilator therapy
* 6-minute walk test to assess functional status and follow the progress of therapy
* Computed tomography (CT) scan to evaluate pulmonary vascular anatomy and exclude other causes of pulmonary hypertension
* Ventilation/perfusion scan to evaluate lung function and exclude other causes of pulmonary hypertension [Source: 05_Stoelting.md] **Vasodilator Test for PAH** The vasodilator test is used to determine the potential response to vasodilator therapy. A potent vasodilator such as prostacyclin, NO, adenosine, or prostaglandin E1 is administered, and the result is considered positive if PVR and mean pulmonary arterial pressure both decrease acutely by 20% or more. Only about one-fourth of patients show a favorable response to the vasodilator test. [Source: 05_Stoelting.md] **Prognosis and Management of PAH** PAH is a devastating clinical condition with a median period of survival after diagnosis of 2.8 years. Patients with idiopathic PAH are at risk of perioperative right ventricular failure, hypoxemia, and coronary ischemia. Effective therapies may be specific to the primary mechanism of pulmonary hypertension in a given patient, and patients with congenital heart disease should have thorough investigation for all potential contributing etiologies to pulmonary hypertension that may require specific therapy. [Source: 2018 AHA_ACC Guidelines on Adult Congenital Heart Disease.md] References: * 2018 AHA_ACC Guidelines on Adult Congenital Heart Disease.md
* 05_Stoelting.md
* Stout et al. (2019). Circulation, 139(10), e698-e800. DOI: 10.1161/CIR.0000000000000603
* Zach KJ, Ramakrishna H, Chandrasekaran K, et al. (2015). Ann Card Anaesth, 18(3), 252-256.
* Duffels MGJ, Engelfriet PM, Berger RMF, et al. (2007). Int J Cardiol, 120(2), 198-204.
* Lowe BS, Therrien J, Ionescu-Ittu R, et al. (2011). J Am Coll Cardiol, 58(4), 538-546.
* Van De Bruaene A, Delcroix M, Pasquet A, et al. (2011). Int J Cardiol, 152(2), 192-195.
* Barst RJ, Ivy DD, Foreman AJ, et al. (2014). Am J Cardiol, 113(2), 147-155.
* D'Alto M, Romeo E, Argiento P, et al. (2013). Int J Cardiol, 164(3), 323-326.
* Engelfriet PM, Duffels MGJ, Möller T, et al. (2007). Heart, 93(8), 682-687.
* Manes A, Palazzini M, Leci E, et al. (2014). Eur Heart J, 35(5), 716-724.
* O'Donnell C, Ruygrok PN, Whyte K, et al. (2010). Heart Lung Circ, 19(10), 713-716.
* Simonneau G, Robbins IM, Berghetti M, et al. (2009). J Am Coll Cardiol, 54(2), S43-S54.
* Dincer HE, Presberg KW. (2004). Clin Pulm Med, 11(2), 40-53.",mean pulmonary artery pressure of more than 25 mm Hg at rest,3,3,20251112_083905,manual
what is the recommended positive end expiratory pressure (PEEP) during one lung ventilation?,"**Recommended Positive End-Expiratory Pressure (PEEP) during One Lung Ventilation (OLV)** During one lung ventilation, the optimal PEEP level is not clearly defined, and it may vary depending on individual patient factors and lung function. However, based on the provided clinical guidelines and medical literature, the following recommendations can be made: * **General Guidelines**: PEEP should be set at 3-10 cm H2O during OLV, titrated to the highest lung compliance (Source: step by step management of onelung ventilation CJA 2014.md)
* **Pre-existing Restrictive Pulmonary Disease or Obesity**: Patients may benefit from a PEEP > 5 cmH2O to approximately 12 cmH2O during OLV (Source: One Lung Ventilation.md)
* **Significant Obstructive Pulmonary Disease**: Patients may require lower levels of PEEP, and the level of auto-PEEP should be detected to allow for complete expiration (Source: One Lung Ventilation.md)
* **Low Tidal Volume and PEEP**: Combining low levels of PEEP (< 5 cmH2O) with low tidal volumes (< 5 ml/kg) predisposes to poor aeration and development of atelectasis (Source: One Lung Ventilation.md) The optimal PEEP level during OLV should be determined by titration based on individual compliance of the respiratory system. In patients with normal pulmonary function, extrinsic PEEP tends to increase the end-expiratory pressure towards the lower inflection point of the pressure-volume curve. In patients with obstructive lung disease, extrinsic PEEP may create or enhance intrinsic PEEP during OLV. **Important Considerations**: * Patients may benefit from a higher PEEP level in the presence of pre-existing restrictive pulmonary disease or obesity.
* Patients with significant obstructive pulmonary disease may require lower levels of PEEP.
* The level of auto-PEEP should be detected to allow for complete expiration.
* Combining low levels of PEEP with low tidal volumes predisposes to poor aeration and development of atelectasis. **References**: * step by step management of onelung ventilation CJA 2014.md
* One Lung Ventilation.md
* wk_3b_slinger_06_olv_management.md Note: The optimal PEEP level during OLV may vary depending on individual patient factors and lung function. These recommendations should be used as a general guideline, and the optimal PEEP level should be determined by titration based on individual patient needs.",3-10 cm water,3,3,20251112_083905,manual
Should vitamin K be co-administered with PCC?,"Should vitamin K be co-administered with PCC? According to the provided context, the answer is yes. [Source: Blood components updated V2 final.md]
When using PCC, it is essential to also give 5 -10 mg of intravenous vitamin K due to the short half-life of factor VII (6 h) [50]. This is to ensure rapid reversal of warfarin anticoagulation. Additionally, [Source: ASRA Guidelines 2025.md] states that when there is an elevated INR without major bleeding, oral vitamin K can be used to reverse warfarin. Intravenous vitamin K can be administered when there is active bleeding. Furthermore, [Source: 2014 ACC_AHA Guideline for the Management of Patients With Valvular Heart Disease.md] recommends the use of vitamin K in patients with an INR >10 who are not bleeding, in addition to withholding VKA therapy. When the INR falls to a safe level, VKA therapy is restarted with the dose adjusted as needed to maintain therapeutic anticoagulation. It is essential to note that vitamin K should be administered to maintain reversal, even if other agents are used [Source: Anesthesia Notes.md]. Therefore, based on the provided context, it is recommended to co-administer vitamin K with PCC to ensure rapid and effective reversal of warfarin anticoagulation.","Yes, 5–10mg intravenous vitamin K should be given with PCC to maintain correction.",3,3,20251112_083905,manual
Is cryoprecipitate the first-line therapy for fibrinogen replacement?,"Based on the provided context, the current recommendations for fibrinogen replacement therapy are as follows: 1. **Fibrinogen Concentrates as First-Line Therapy**: The British Society of Haematology guidelines [Source: Blood components updated V2 final.md] state that fibrinogen concentrates are now considered the first-line therapy for replacing fibrinogen in many European countries [39, 40]. However, the clinical evidence for superiority of fibrinogen concentrates over cryoprecipitate is lacking [40].
2. **Cryoprecipitate as Alternative Option**: Cryoprecipitate is still considered a viable alternative for fibrinogen replacement, particularly in situations where fibrinogen concentrates are not available [39]. Cryoprecipitate contains fibrinogen, factor VIII, and von Willebrand factor [Source: Anesthesia Notes.md].
3. **Indications for Cryoprecipitate**: Cryoprecipitate is indicated for fibrinogen replacement in patients with hypofibrinogenemia (<100 mg/dL) [Source: Anesthesia Notes.md]. It is also used in hemophilia A (if a virus-inactivated Factor VIII concentrate is not available), von Willebrand's disease, and factor XIII deficiency [Source: Anesthesia Notes.md].
4. **Dosage for Cryoprecipitate**: The recommended dose for cryoprecipitate is 1 unit/10 kg, with a usual dose of 8-12 units [Source: Anesthesia Notes.md].
5. **Fibrinogen Concentrates vs. Cryoprecipitate**: A recent large trial found that fibrinogen concentrate was noninferior to cryoprecipitate in patients who developed clinically significant bleeding and hypofibrinogenemia after cardiac bypass [41]. In summary, while fibrinogen concentrates are now considered the first-line therapy for fibrinogen replacement in many European countries, cryoprecipitate remains a viable alternative option, particularly in situations where fibrinogen concentrates are not available. Further research is needed to clarify the superiority of fibrinogen concentrates over cryoprecipitate. References: [39] Any RhD group may be transfused. Fresh frozen plasma contains a very small amount of red cell stroma and sensitisation following administration of RhD-positive plasma to an RhD-negative individual is very unlikely to occur [38]. [40] Fibrinogen concentrates are produced as pasteurised, lyophilised products from pooled donors that undergo puri /uniFB01 cation, viral inactivation and removal processes, and do not require cross-matching [39]. [41] A recent large trial found that /uniFB01 brinogen concentrate was noninferior to cryoprecipitate in patients who developed clinically signi /uniFB01 cant bleeding and hypo /uniFB01 brinogenaemia after cardiac bypass [41].","Yes, cryoprecipitate is the standard concentrated source of fibrinogen.",3,3,20251112_083905,manual
what are some common complication that occurs after MI,"**Common Complications After Myocardial Infarction (MI)** A myocardial infarction can lead to various complications. Based on the provided clinical guidelines and medical literature, some common complications include: **Cardiac Dysrhythmias** * Ventricular tachycardia (VT) is common in acute MI, with short periods of nonsustained VT not predisposing to sustained VT or ventricular fibrillation (VF). [Source: 01_Stoelting.md]
* Sustained or hemodynamically significant VT requires prompt treatment with electrical cardioversion. [Source: 01_Stoelting.md]
* Asymptomatic VT can be treated with intravenous lidocaine or amiodarone. [Source: 01_Stoelting.md]
* Implantation of a cardioverter-defibrillator may be indicated in patients with recurrent VT or VF despite adequate revascularization. [Source: 01_Stoelting.md] **Ventricular Fibrillation** * VF occurs in 3% to 5% of patients with acute MI, usually within the first 4 hours after the event. [Source: 01_Stoelting.md]
* Rapid defibrillation with 200 to 300 J of energy is necessary when VF occurs. [Source: 01_Stoelting.md]
* Prophylactic lidocaine is not necessary if electrical defibrillation can be promptly accomplished. [Source: 01_Stoelting.md]
* Amiodarone is effective in controlling ventricular tachydysrhythmias, especially after MI. [Source: 01_Stoelting.md]
* Administration of β-blockers may decrease the early occurrence of VF. [Source: 01_Stoelting.md]
* Hypokalemia is a risk factor for VF. [Source: 01_Stoelting.md] **Other Complications** * **Pericarditis**: Acute pericarditis occurs in 10% to 15% of patients 1 to 4 days after MI. [Source: 01_Stoelting.md]
* **Mitral Regurgitation**: Severe mitral regurgitation due to papillary muscle rupture can occur after acute MI, especially after an inferior wall MI. [Source: 01_Stoelting.md]
* **Ventricular Septal Rupture**: Total papillary muscle rupture usually leads to death within 24 hours, and prompt surgical repair is required. [Source: 01_Stoelting.md] **Patient Safety Considerations** * Patients with a history of MI should have elective surgery delayed for at least 30 days. [Source: 01_Stoelting.md]
* The presence of aortic stenosis is associated with a two- to three-fold increase in the risk of perioperative cardiac morbidity and mortality. [Source: 01_Stoelting.md]
* Patients with critical aortic stenosis have the highest risk of cardiac decompensation after noncardiac surgery. [Source: 01_Stoelting.md] **Critical Clinical Recommendations** * Patients with acute MI should be closely monitored for signs of cardiac complications.
* Prompt treatment is necessary for sustained or hemodynamically significant VT and VF.
* Asymptomatic VT can be treated with intravenous lidocaine or amiodarone.
* Patients with a history of MI should have elective surgery delayed for at least 30 days.
* The presence of aortic stenosis should be noted, and patients with critical aortic stenosis should be closely monitored for signs of cardiac decompensation.","acute pericarditis can occur 1 to 4 days after an MI in 10-15% of patients, also Mitral regurgitation, ventricular septal rupture, cardiac dysrhythmias, CHF, cardiogenic shock , acute myocardial rupture, ischemic or hemmorhagic stroke",3,3,20251112_083905,manual
"in patients with restrictive lung disease, what is a reasonable inpiratory to expiratory ratio (I:E)?","**Inspiratory to Expiratory Ratio (I:E) in Patients with Restrictive Lung Disease** According to the provided clinical guidelines and medical literature, patients with restrictive lung disease require a different ventilatory approach compared to those with obstructive lung disease. **Recommendations for Restrictive Lung Disease:** * The inspiratory to expiratory (I:E) ratio should be adjusted to 1:1-2:1 to maximize inspiratory time, thereby reducing peak and plateau ventilatory pressures. [Source: step by step management of onelung ventilation CJA 2014.md]
* Permissive hypercapnea may be considered to avoid exacerbating lung injury, and PaCO2 levels up to 70 mmHg are well tolerated in the short term. [Source: wk_3b_slinger_06_olv_management.md]
* The respiratory rate should be adjusted to divide a given minute volume by a higher respiratory frequency, which may be beneficial in reducing peak and plateau ventilatory pressures. However, this approach may result in reduced CO2 elimination due to increased anatomic dead space ventilation. [Source: wk_3b_slinger_06_olv_management.md] **Clinical Considerations:** * Patients with restrictive lung disease may require more aggressive ventilatory support to maintain adequate oxygenation and ventilation.
* The use of pressure-control ventilation (PCV) may be beneficial in reducing ventilatory pressures, but the evidence is controversial. [Source: step by step management of onelung ventilation CJA 2014.md]
* The inspiratory to expiratory ratio should be adjusted according to the patient's underlying lung mechanics, and extreme airflow obstruction may require very long expiratory times. **Summary:** In patients with restrictive lung disease, a reasonable inspiratory to expiratory ratio (I:E) is 1:1-2:1, which maximizes inspiratory time and reduces peak and plateau ventilatory pressures. Permissive hypercapnea may be considered, and the respiratory rate should be adjusted to divide a given minute volume by a higher respiratory frequency. However, this approach may result in reduced CO2 elimination due to increased anatomic dead space ventilation. **References:** [Source: wk_3b_slinger_06_olv_management.md]
[Source: step by step management of onelung ventilation CJA 2014.md]",1:1 up to 2:1,3,3,20251112_083905,manual
